## Abstract One hundred milliliters of an inactivated hepatitis B vaccine (20 /mΜg/ml) were inoculated intravenously into two colonyβborn infant chimpanzees. Immediately thereafter each received hepatitis B virus from a documented infectious inoculum intravenously at a separate site. Neither chimpa
Hepatitis B immunoglobulin immunoprophylaxis for hepatitis B: High, low, or no dose?
β Scribed by Ed Gane
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 80 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22151
No coin nor oath required. For personal study only.
β¦ Synopsis
Key Points
- Transplantation for HBV-related HCC is increasing in the West, whilst HBV-relate liver failure is decreasing. 2. Combination lamivudine plus HBIG reduces the risk of HBV recurrence to less than 5%. 3. Low-dose IM HBIG ihas similar efficacy and better cost effectiveness than high-dose IV HBIG when combined with oral nucleos(t)ide therapy. 4. HBIG may be discontinued in low risk recipients (undetectable HBV DNA prior to transplant). 5. Combination of new potent antivirals without cross resistance may minimise the future need for post-operative HBIG. Liver Transpl 16:S36-S39, 2010. V C 2010 AASLD.
π SIMILAR VOLUMES
The prevention of hepatitis B virus (HBV) recurrence is essential after liver transplantation in patients infected with HBV. We evaluated the efficacy of primary high-dose hepatitis B immunoglobulin (HBIG) monotherapy and rescue antiviral therapy in 639 HBV-infected adult patients who underwent livi
Current protocols for prophylaxis against allograft reinfection after liver transplantation for chronic hepatitis B virus (HBV) infection include the administration of large doses of hepatitis B immune globulin (HBIG), with considerable associated economic costs. Monotherapeutic prophylaxis with lam
A considerable proportion of liver transplantation recipients who receive hepatitis B immunoglobulin (HBIG) monotherapy for hepatitis B virus (HBV) prophylaxis develop resistance to HBIG. We retrospectively assessed the efficacy of HBV prophylaxis in 1524 patients who received primary high-dose HBIG
A combination of hepatitis B immunoglobulin (HBIG) and nucleos(t)ide analogues (NUCs) is currently recommended as prophylaxis against the recurrence of hepatitis B virus (HBV) after liver transplantation (LT), but the optimal protocol is a matter of controversy. The aim of this study was the identif